

# Xin Tian

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8089029/publications.pdf>

Version: 2024-02-01

43  
papers

2,598  
citations

331670

21  
h-index

276875

41  
g-index

43  
all docs

43  
docs citations

43  
times ranked

3446  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. <i>Lancet Oncology</i> , The, 2015, 16, 169-176.	10.7	344
2	Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. <i>Blood</i> , 2017, 129, 1469-1479.	1.4	276
3	Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. <i>Blood</i> , 2015, 126, 2213-2219.	1.4	198
4	The BASILICA Trial. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1240-1252.	2.9	183
5	Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. <i>Blood</i> , 2018, 131, 2357-2366.	1.4	166
6	High Prevalence of Respiratory Ciliary Dysfunction in Congenital Heart Disease Patients With Heterotaxy. <i>Circulation</i> , 2012, 125, 2232-2242.	1.6	158
7	Time Course of LDL Cholesterol Exposure and Cardiovascular Disease Event Risk. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1507-1516.	2.8	155
8	Atypical <i>Pneumocystis jirovecii</i> pneumonia in previously untreated patients with CLL on single-agent ibrutinib. <i>Blood</i> , 2016, 128, 1940-1943.	1.4	149
9	Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. <i>Haematologica</i> , 2015, 100, 1571-1578.	3.5	137
10	Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. <i>Blood</i> , 2021, 137, 185-189.	1.4	110
11	Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations. <i>New England Journal of Medicine</i> , 2020, 383, 498-500.	27.0	84
12	Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib. <i>JAMA Oncology</i> , 2016, 2, 1656.	7.1	75
13	Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model. <i>Journal of Clinical Oncology</i> , 2021, 39, 576-585.	1.6	74
14	Iron, Inflammation, and Early Death in Adults With Sickle Cell Disease. <i>Circulation Research</i> , 2015, 116, 298-306.	4.5	71
15	Association of Cumulative Systolic Blood Pressure With Long-Term Risk of Cardiovascular Disease and Healthy Longevity. <i>Hypertension</i> , 2021, 77, 347-356.	2.7	43
16	Airway Ciliary Dysfunction and Sinopulmonary Symptoms in Patients with Congenital Heart Disease. <i>Annals of the American Thoracic Society</i> , 2014, 11, 1426-1432.	3.2	38
17	BASILICA Trial: One-Year Outcomes of Transcatheter Electrosurgical Leaflet Laceration to Prevent TAVR Coronary Obstruction. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010238.	3.9	34
18	A novel method to expand large numbers of CD56+ natural killer cells from a minute fraction of selectively accessed cryopreserved cord blood for immunotherapy after transplantation. <i>Cytotherapy</i> , 2015, 17, 1582-1593.	0.7	28

#	ARTICLE	IF	CITATIONS
19	Nonparametric Estimation of Conditional Distributions and Rank-Tracking Probabilities With Time-Varying Transformation Models in Longitudinal Studies. <i>Journal of the American Statistical Association</i> , 2013, 108, 971-982.	3.1	27
20	Persistence of recipient human leucocyte antigen (<sc>HLA</sc>) antibodies and production of donor <sc>HLA</sc> antibodies following reduced intensity allogeneic haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2014, 166, 425-434.	2.5	26
21	Establishing normative nasal nitric oxide values in infants. <i>Respiratory Medicine</i> , 2015, 109, 1126-1130.	2.9	22
22	Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL. <i>Blood</i> , 2019, 133, 2452-2455.	1.4	22
23	Clinical Outcomes in Patients with Multi-Hit <i>TP53</i> Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Clinical Cancer Research</i> , 2021, 27, 4531-4538.	7.0	20
24	Immune Response Following Quadrivalent Human Papillomavirus Vaccination in Women After Hematopoietic Allogeneic Stem Cell Transplant. <i>JAMA Oncology</i> , 2020, 6, 696.	7.1	18
25	Airway ciliary dysfunction: Association with adverse postoperative outcomes in nonheterotaxy congenital heart disease patients. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 755-763.e7.	0.8	17
26	A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo-immunized patients. <i>British Journal of Haematology</i> , 2020, 189, 551-558.	2.5	17
27	Airway ciliary dysfunction and respiratory symptoms in patients with transposition of the great arteries. <i>PLoS ONE</i> , 2018, 13, e0191605.	2.5	17
28	Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2020, 61, 2375-2382.	1.3	16
29	BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL. <i>Blood Advances</i> , 2022, 6, 1732-1740.	5.2	13
30	Over-expression of PD-1 Does Not Predict Leukemic Relapse after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 216-222.	2.0	11
31	A phenotypic risk score for predicting mortality in sickle cell disease. <i>British Journal of Haematology</i> , 2021, 192, 932-941.	2.5	9
32	Nonparametric Estimation of Conditional Distribution Functions and Rank-Tracking Probabilities With Longitudinal Data. <i>Journal of Statistical Theory and Practice</i> , 2013, 7, 259-284.	0.5	8
33	Combined haploidentical and cord blood transplantation for refractory severe aplastic anaemia and hypoplastic myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2021, 193, 951-960.	2.5	8
34	Rapid donor T cell engraftment increases the risk of chronic graft-versus-host disease following salvage allogeneic peripheral blood hematopoietic cell transplantation for bone marrow failure syndromes. <i>American Journal of Hematology</i> , 2013, 88, 874-882.	4.1	5
35	Estimation of rank-tracking probabilities using nonparametric mixed-effects models for longitudinal data. <i>Statistics and Its Interface</i> , 2014, 7, 87-99.	0.3	5
36	Distinct Biomarker Profiles in Ex Vivo T Cell Depletion Graft Manipulation Strategies: CD34+ Selection versus CD3+/19+ Depletion in Matched Sibling Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 460-466.	2.0	3

#	ARTICLE	IF	CITATIONS
37	Ex Vivo Nicotinamide-Expanded (NAM-Expanded) Unrelated Cord Bloodtransplantation (UCB) for Refractory Severe Aplastic Anemia Results in Rapid Engraftment and Expedites Immune Recovery. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S210-S211.	2.0	3
38	A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2020, 95, E310-E313.	4.1	3
39	Nonparametric estimation of risk tracking indices for longitudinal studies. <i>Statistical Methods in Medical Research</i> , 2020, 29, 481-497.	1.5	2
40	A prospective evaluation on the interaction of fluconazole and voriconazole on serum concentrations of budesonide in patients treated for gastrointestinal GVHD. <i>Bone Marrow Transplantation</i> , 2020, 55, 1085-1092.	2.4	2
41	Statistical Indices for Risk Tracking in Longitudinal Studies. <i>ICSA Book Series in Statistics</i> , 2017, , 293-311.	0.2	1
42	Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study. <i>Leukemia and Lymphoma</i> , 2021, 62, 1816-1827.	1.3	0
43	Haematopoietic stem cell transplant patients have a high initial failure rate to hepatitis B vaccination that can be overcome with subsequent vaccination series. <i>British Journal of Haematology</i> , 2022, 196, 1404-1407.	2.5	0